Literature DB >> 22402324

Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype.

Roger M Lane1, Yunsheng He.   

Abstract

Retrospective data are presented to support a spectrum of early Alzheimer's disease (AD) along a continuum defined by gender and genotype. The putative neurodegenerative mechanisms driving distinct phenotypes at each end of the spectrum are glial hypoactivity associated with early failure of synaptic cholinergic neurotransmission and glial overactivation associated with loss of neural network connectivity due to accelerated age-related breakdown of myelin. In early AD, male butyrylcholinesterase K-variant carriers with one or two apolipoprotein ɛ4 alleles have prominent medial temporal atrophy, synaptic failure, cognitive decline, and accumulation of aggregated beta-amyloid peptide. Increasing synaptic acetylcholine in damaged but still functional cholinergic synapses improves cognitive symptoms, whereas increasing the ability of glia to support synapses and to clear beta-amyloid peptide might be disease-modifying. Conversely, chronic glial overactivation can also drive degenerative processes and in butyrylcholinesterase K-variant negative females generalized glial overactivation may be the main driver from mild cognitive impairment to AD. Females are more likely than males to have accelerated age-related myelin breakdown, more widespread white matter loss, loss of neural network connectivity, whole brain atrophy, and functional decline. Increasing extracellular acetylcholine levels blocks glial activation, reduces myelin loss and damage to neural network connectivity, and is disease-modifying. Between extremes characterized by gender, genotype, and age, pathophysiology may be mixed and this spectrum may explain much of the heterogeneity of amnestic mild cognitive impairment. Preservation of the functional integrity of the neural network may be an important component of strengthening cognitive reserve and significantly delaying the onset and progression of dementia, particularly in females. Prospective confirmation of these hypotheses is required. Implications for future research and therapeutic opportunities are discussed.
Copyright © 2013 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22402324     DOI: 10.1016/j.jalz.2010.12.005

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  8 in total

1.  Butyrylcholinesterase levels and subjective effects of smoked cocaine in healthy cocaine users.

Authors:  Paula Askalsky; Raj K Kalapatapu; Richard W Foltin; Sandra D Comer
Journal:  Am J Drug Alcohol Abuse       Date:  2014-10-16       Impact factor: 3.829

2.  Phenotypic Displays of Cholinergic Enzymes Associate With Markers of Inflammation, Neurofibrillary Tangles, and Neurodegeneration in Pre- and Early Symptomatic Dementia Subjects.

Authors:  Unnur D Teitsdottir; Taher Darreh-Shori; Sigrun H Lund; Maria K Jonsdottir; Jon Snaedal; Petur H Petersen
Journal:  Front Aging Neurosci       Date:  2022-05-26       Impact factor: 5.702

Review 3.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

Review 4.  White matter and cognition: making the connection.

Authors:  Christopher M Filley; R Douglas Fields
Journal:  J Neurophysiol       Date:  2016-08-10       Impact factor: 2.714

5.  Sex Differences in the Genetic Architecture of Alzheimer's Disease.

Authors:  Logan Dumitrescu; Elizabeth Rose Mayeda; Kavya Sharman; Annah M Moore; Timothy J Hohman
Journal:  Curr Genet Med Rep       Date:  2019-01-21

6.  De novo transcriptome sequencing and digital gene expression analysis predict biosynthetic pathway of rhynchophylline and isorhynchophylline from Uncaria rhynchophylla, a non-model plant with potent anti-alzheimer's properties.

Authors:  Qianqian Guo; Xiaojun Ma; Shugen Wei; Deyou Qiu; Iain W Wilson; Peng Wu; Qi Tang; Lijun Liu; Shoukun Dong; Wei Zu
Journal:  BMC Genomics       Date:  2014-08-12       Impact factor: 3.969

Review 7.  Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.

Authors:  Nagaendran Kandiah; Ming-Chyi Pai; Vorapun Senanarong; Irene Looi; Encarnita Ampil; Kyung Won Park; Ananda Krishna Karanam; Stephen Christopher
Journal:  Clin Interv Aging       Date:  2017-04-18       Impact factor: 4.458

8.  A novel mutation in the BCHE gene and phenotype identified in a child with low butyrylcholinesterase activity: a case report.

Authors:  Rentao Yu; Yanzhi Guo; Yunjie Dan; Wenting Tan; Qing Mao; Guohong Deng
Journal:  BMC Med Genet       Date:  2018-04-10       Impact factor: 2.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.